Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. (NASDAQ: RLMD) on December 12, 2025. The report details the Board of Directors' approval of amended and restated employment agreements for the company's executive officers, effective January 1, 2026.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation adjustments.
Material Changes
The primary material change involves salary increases for four executive officers, effective January 1, 2026. The specific adjustments are as follows:
- Sergio Traversa (CEO): Salary increased from $787,787 to $827,176 per year.
- Paul Kelly (COO): Salary increased from $499,800 to $524,790 per year. Severance provisions were updated to include 12 months of compensation for termination without cause (or resignation for good reason) and 18 months in the event of a Change in Control.
- Maged Shenouda (CFO): Salary increased from $558,990 to $586,940 per year. Severance provisions mirror those of the COO, with health benefits continuing for the longer of 12 months or until Medicare eligibility.
- Charles Ence (Chief Accounting and Compliance Officer): Salary increased from $548,990 to $576,440 per year. Severance provisions mirror those of the COO and CFO.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance, operational outlook, or new risk factors. The document notes that the material terms of the agreements, aside from the salary increases and specific severance clarifications, remain unchanged from previous disclosures. The agreements are qualified in their entirety by reference to the full text filed as Exhibits 10.1 through 10.4.
Investor Verification Checklist
- Verify the total annualized cost increase for executive compensation based on the new salary figures.
- Review the full text of Exhibits 10.1 through 10.4 to understand the complete scope of severance triggers and "Change in Control" definitions.
- Confirm the effective date of January 1, 2026, for the new compensation terms.
- Check subsequent filings for any impact on the company's cash burn rate given the increased fixed compensation costs.